At UK Biocentre, we have the capability to accurately analyse large volumes of samples, and the space and expertise to continue to expand our operations.
With the support of numerous partners, we have installed state-of-the-art robotic equipment and other technology that enables us to analyse tens of thousands of samples in a matter of hours each day. Accuracy remains our number one priority, and we continue to work closely with the NHS and PHE to ensure we meet the highest standards every time.
To meet the growing demand, we have increased the number of people working with us. Starting as a staff team of just 35, we now have the support of over 450 people working with us on shift patterns 24/7. We are very grateful to all the highly experienced molecular scientists, technicians, bioinformaticians and other colleagues who support us.
UK Biocentre has been testing swabs to support clinical trials of the Oxford coronavirus vaccine ChAdOx1 nCoV-19, developed by the University of Oxford in collaboration with biopharmaceutical company AstraZeneca.
In November 2020, interim trial data was announced showing that the vaccine is effective at preventing COVID-19 and offers a high level of protection.
The clinical trials will now continue to final analysis to provide more information about the efficacy and safety of the vaccine.
An important part of the long-term strategy against COVID-19 is to study the behaviour of the coronavirus. To support this, we are freezing and storing positive samples in secure facilities, so that they can be made available for future research.